News

A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according to a study led by researchers at the University of California, Irvine. The team also identified ERV expression signatures that may be

A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A. Anna Ioannidou of Imperial College London, U.K., and colleagues present these findings in the open-access journal PLOS Medicine. Some factors associated with higher risk of prostate cancer cannot

The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study from Karolinska Institutet published in the journal European Urology. The results provide support for organised prostate cancer testing in Sweden, researchers say. A

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team led by investigators at Massachusetts General

Calculating a person’s risk of developing prostate cancer using results from two blood markers would improve the accuracy of screening for the disease, reports a new study led by a UCL researcher. Prostate cancer is the most common form of cancer in men, with more than 10,000 men dying from the disease every year in

A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has significantly increased for men 45 and older and coincides with recommendations against routine prostate cancer screenings. “This study is the first to document a continued rise in metastatic prostate cancer using the most up-to-date population dataset,” said